这2年新基来拉度胺的销售增长其实是靠强生的Darzalex拉动的。组合疗法效果太好，PFS大幅度延长让病人吃来拉度胺的时间变得很长很长。

At a median follow-up of 28 months, “we’re nowhere near” the median progression-free survival for the Darzalex regimen, he said. In the phase 3 study, dubbed Maia, Revlimid and dexamethasone recorded median progression-free survival of 31.9 months. Darzalex also helped drive up complete response rates to 48% versus 25% for Rd.

Together, the data “really represents a practice-changing moment,” Wildgust said. “For those patients today whom hematologists would think about giving Rev-dex, you should really be using” Darzalex alongside the combo. “It’s very convincing,” he added.